|

Reflections on BGI’s Gulf Partnerships: Localisation Is Not Sovereignty

ByJose Leal

As the Strait of Hormuz crisis intensifies and persists, major container lines have suspended or rerouted Gulf calls around the Cape of Good Hope, adding ten to fourteen days to deliveries of medical devices, consumables, and diagnostic inputs. Freight and insurance costs spiked. Airspace restrictions compounded the disruption: medical and humanitarian supplies including IV fluids, antibiotics, and diagnostic tests were reported stuck in Dubai, with clinics across Africa and Asia facing imminent stock-outs. In the Gulf, health systems that import essentially all of their diagnostic consumables faced the same exposure.

This is the immediate dimension of diagnostic sovereignty: when the supply chain breaks, you find out very quickly what you actually control.

But there is a second dimension, longer-term and less visible, that I think is at least as consequential. Data is the substrate from which the next generation of diagnostics will be built. New disease mechanisms, new treatment targets, new biomarkers: these will emerge from large-scale genomic and clinical datasets analysed by AI (I’d still like to believe that bioinformaticians like myself will be the ones controlling the AI in this research, but that is for a different article). The population that generates the data and controls its use holds the upstream position in that value chain. The population that generates the data but cedes its use to external platforms holds a different position: it pays twice, first to collect the data, then to licence back the insights extracted from it. From a personal insurance premium to a national cancer screening programme, the downstream consequences of that asymmetry will run for decades.

I’ve been researching the issue of health-related sovereignty in the Gulf, in particular because as I am building health tech innovation infrastructure out of Qatar the issue of procurement came to the fore, and made me aware of the lack of Diagnostics Sovereignty that characterises the region today. From that position, the BGI relationship across the Gulf looks less like a procurement story and more like a test of whether the region understands what sovereignty in the age of AI actually requires.

Localization is not the same as sovereignty

The most seductive trap in Gulf health industrialisation right now is confusing the two. Local testing volume, instruments on the ground, a laboratory with a Saudi or Emirati address, a workforce meeting the quotas for nationals. These are real progress, mind you, but they are not sovereignty if the operating logic of the system, i.e. the software, the reference databases, the interpretation pipelines, the contractual terms, sits elsewhere.

In March 2025, BGI’s Genalive venture, a joint operation between BGI Almanahil Health and Tibbiyah Holding, secured a 950 million RMB contract, approximately USD 130 million, from NUPCO covering roughly 930,000 genetic tests across 83 public hospitals in Saudi Arabia. NGS, pathology, cytogenetics, Sanger sequencing. BGI, the sole owner of BGI Almanahil Health, is China’s largest genomics and sequencing conglomerate, operating a vertically integrated stack of sequencers, wet labs and AI analytics. They describe the Genalive contract as the largest outsourced testing contract in public hospitals it has ever reported. This is clearly not a pilot. That is the largest genomic testing infrastructure deployment in Gulf history, and it is BGI-centred.

Behind that contract, Saudi citizens are providing biological specimens for genetic characterisation under the reasonable assumption that such data will be safe and that the aggregated insights emerging from their population will remain a Saudi asset. I think that those assumptions deserve scrutiny. Not because the contract is in any way unlawful, but because the architecture within which data is generated determines what “safe” and “ours” can actually mean in practice.

Two months after the Genalive announcement, in late April and early May 2025, BGI Chairman Wang Jian led a delegation to Riyadh. In one week: a meeting with the Saudi Minister of Health, a meeting with the SFDA CEO, meetings with NUPCO and the National Health Holding Company, a session with the Saudi Research, Development and Innovation Authority, and a signed MOU with King Saud University for genomics and precision medicine training. BGI’s own communications frame this as support for Saudi Vision 2030 and the development of a genomics-driven national health system.

That is not a vendor relationship. That is the architecture of a strategic dependency being constructed simultaneously at the levels of government, procurement, regulation, and education. Once a genomics programme is built around a particular sequencing ecosystem, validated reagent chain, sample logistics model, analysis pipeline, and training curriculum, the switching costs rise sharply. What starts as diversification can end as a different form of lock-in. The question is never just where the building is. The question is where the operational leverage resides.

The data layer is where the real sovereignty question sits

A BGI-centred genomics programme does not end with test kits or sequencers. It extends into sample accessioning, laboratory information systems, analysis pipelines, storage architecture, variant interpretation, report generation, and secondary research use. Even where data is formally hosted inside national borders, the practical architecture may depend on proprietary software, vendor-managed updates, remote support, and reference databases that tie the operator to the ecosystem that designed the pipeline.

The point I’m making here is that local hosting does not equal local control.

This matters more than it did five years ago because biological data has been explicitly reclassified as a strategic asset in US national security policy. In March 2023, the US Department of Commerce added BGI Research and BGI Tech Solutions (Hong Kong) to its Entity List on the explicit grounds that their collection and analysis of genetic data “present a significant risk of diversion to China’s military programs.” Not civilian surveillance: military programs! The BIOSECURE Act, enacted in December 2025 as part of the NDAA, went further: it restricts US federal agencies from procuring biotechnology equipment or services from BGI and affiliated entities, and from contracting with companies that depend on them.

The language is American, but the underlying shift is broader. Genomic and multi-omic data are being treated more like telecoms infrastructure than routine patient records, closer to energy systems than to clinical files. A Gulf institution in deep operational relationship with BGI is not only choosing a supplier. It is accepting growing friction with legal and regulatory systems in Washington and increasingly Brussels, friction that will constrain where Gulf-developed diagnostics can be used, who will partner on drug development programmes, and which regulatory submissions will proceed without challenge.

There is also a specific legal gap that current GCC frameworks do not address. All six GCC states now have personal data protection laws that treat health and genetic information as sensitive and tightly regulate identifiable patient records. But those laws are largely silent on derived, non-personal artefacts: the model weights, variant-frequency databases, and algorithm parameters that a vendor like BGI can extract from population-scale use of its pipelines. These artefacts do not contain named patients. They do contain Gulf population biology, and they can leave the region without triggering a breach notification under any current GCC instrument. The law protects the person identity, but it does not yet protect what a sophisticated vendor or state actor learns about the population by processing everyone in it.

In Saudi Arabia, that asymmetry matters more than anywhere else in the GCC, because the Genalive JV sits directly inside the public hospital system at scale.

BGI across the Gulf: the outlier in context

Saudi Arabia is not the whole story.

Across the rest of the GCC, Chinese sequencing companies are present more as technology vendors and would-be partners than as operators of national genome infrastructures. BGI courted Qatar as far back as 2013, announcing plans to establish a genome sequencing institute at Sidra as a regional hub. A decade later, Qatar’s national genome programme runs on Illumina’s DRAGEN platform; its major translational partnerships, including the BeginNGS newborn screening programme with Sidra Medicine, are US and European. There is no evidence that Qatar’s core genome datasets are running through Chinese sequencers or clouds today. * Note, I would never assume that Americans or Europeans are more trustable in this regard than China; my argument is not agains any one state, but the notion that external states control or access the data unchecked.

In Oman, a government delegation visited BGI’s headquarters and the China National GeneBank in November 2023, and both sides expressed willingness to cooperate on genomics, education, and agriculture. BGI appears on vendor lists for Oman’s genomics market alongside Illumina, Thermo Fisher, and Roche. There is no public evidence of a national-level contract or that the Oman Genome Project’s core sequencing is anchored on a Chinese platform.

In Bahrain, BGI has signed an MOU with Arabian Gulf University, the institution that houses the Al-Jawhara Centre for Molecular Medicine, Genetics, and Inherited Disorders, and where a clinical whole-genome sequencing project with BGI was already underway. That is an academic foothold. Bahrain’s national genome programme is a different matter: it is being designed and implemented by the International Center for Genetic Disease at Brigham and Women’s Hospital and Harvard Medical School, with an explicit national science ownership structure and no Chinese lead. In Kuwait, Chinese sequencing vendors are present as technology options in a growing private market; there is no national-level JV documented.

So, the Saudi Genalive contract is not business as usual. It is the only clearly documented, large-scale, public-sector genomics tender in the GCC where a Chinese ecosystem is structurally embedded in routine clinical testing at national scale. That makes it worth examining on its own terms rather than as representative of a region-wide pattern.

The UAE model and what it proves

In the UAE, the picture is apparently different, but very informative because BGI was also involved.

BGI entered the Emirati Genome Program in 2019 as a core technology provider alongside G42 and Oxford Nanopore. But the architecture was specified from the outset: sequencing would be handled locally, and the Abu Dhabi Department of Health would manage the resulting data. The programme has since evolved into a structure clearly controlled by Emirati entities – DoH Abu Dhabi, G42, M42 – with over 800,000 Emirati citizens sequenced and the Emirati Reference Genome hosted and governed by the Department of Health. BGI provided technology in the early phase. The data stayed, and I assume but was unable to verify, so did the meta-data.

The contrast between the Emirati and Saudi models is not a story about China winning in one place and losing in another. It is a story about governance choices made early, before the architecture hardened. In Abu Dhabi, data custody was specified as a condition of entry. The outcome reflects that specification. In Saudi Arabia, the current public record does not make equivalent commitments visible. That absence is the governance gap the BGI question is actually about.

A Choice

I want to be careful here, because the easy conclusion is the wrong one. The answer is not to reject BGI and return to Western incumbents. Western diagnostic companies have for years been reluctant to localise core manufacturing, slow to transfer meaningful capability, and expensive to maintain at scale. If the Gulf is choosing BGI partly because Western incumbents never offered a credible localisation path, that is a rational response to a real failure. Kudos to BGI and Chinese partners.

But the stronger argument is this: the Gulf must understand what it is buying, and ask harder questions before the architecture is set.

Who owns the raw data and derived datasets? Which software components are auditable? Can the analysis pipeline be ported to another vendor? Are reference databases exportable? What are the contractual terms if geopolitical restrictions escalate? Under what conditions can model weights trained on Gulf populations be retained within Gulf jurisdictions?

Without those questions, localisation is but theatre: equipment onshore, dependency very much intact.

##A The third path

I have written elsewhere about what I see as the fundamental choice the Gulf faces in health data infrastructure, between China’s engineering speed without governance provenance, and the West’s governance architecture without execution speed. (The full argument is in my article Beyond Engineers and Lawyers: A Third Path for Precision Medicine, linked below.)

The Gulf is building from scratch, with the choice still available. The Emirati Genome Program is partial evidence that a third architecture is possible: Chinese technology accepted under specified data custody terms, the programme subsequently consolidated under local institutional control. That is not the final answer, but it is proof that the terms are negotiable if the governance intent is stated up front.

Data infrastructure built with a real consent architecture, local compute requirements, and governance frameworks legible to international partners is a trust asset. Gulf-generated genomic data with clean provenance can go where BGI-processed data increasingly will not: into international regulatory submissions, clinical trial partnerships, and drug development collaborations where provenance questions would otherwise arise. This is not primarily an ethical claim , but a market access claim.

The BGI relationship across the Gulf is important not because it proves China is winning – it probably is, though. But it is important because it reveals how much still depends on choices being made quietly, buried in procurement contracts and MoU terms, before any governance framework has specified what those choices should look like. 

The Gulf has the capital, the governance capacity, and the geopolitical motivation to define its own terms. But will it?

This chapter emerges from my research to my second book The Import Condition: Diagnostics, Sovereignty and the Gulf’s Industrial Moment, coming out in June.

Related reading: Beyond Engineers and Lawyers: A Third Path for Precision Medicine

Sources

  1. “Strait of Hormuz disruption raises costs, supply concerns for medical devices.” Express Healthcare India, 2026. https://www.expresshealthcare.in/news/strait-of-hormuz-disruption-raises-costs-supply-concerns-for-medical-devices-rajiv-nath/453128/
  2. “Asian medical device markets face cost shocks amidst Iran conflict.” Healthcare Asia Magazine, 2026. https://healthcareasiamagazine.com/healthcare/in-focus/asian-medical-device-markets-face-cost-shocks-amidst-iran-conflict
  3. “Hormuz standoff the largest supply shock ever experienced.” PBS NewsHour, 2026. https://www.pbs.org/newshour/show/hormuz-standoff-the-largest-supply-shock-ever-experienced-says-global-energy-expert
  4. “Medical supplies are stuck in Dubai, as clinics around the world face shortages.” NPR, April 6, 2026. https://www.npr.org/2026/04/06/nx-s1-5775543/medical-supplies-stuck-dubai-clinics-world-face-shortages
  5. “Iran war delays delivery of medical goods to other parts of the world.” NPR / WXXI News, March 31, 2026. https://www.wxxinews.org/npr-news/2026-03-31/iran-war-delays-delivery-of-medical-goods-to-other-parts-of-the-world
  6. “Middle East war disrupts pharma air routes, risks cancer drug shortages.” Reuters via Yahoo Finance, 2026. https://www.yahoo.com/news/articles/analysis-middle-east-war-disrupts-060427077.html
  7. BGI Genomics. “BGI Genomics Joint Venture Genalive Secures 950 Million RMB Genetic Testing Tender.” LinkedIn, March 2025. https://www.linkedin.com/posts/bgigenomics_bgi-genomics-joint-venture-genalive-secures-activity-7305908885603655680-hy7Z
  8. BGI Genomics. Facebook post, March 12, 2025. https://www.facebook.com/BGIGenomics/posts/on-march-12th-nupco-awarded-genalive-the-joint-venture-of-bgi-genomics-a-950-mil/1158299289639963/
  9. “BGI Genomics’ Joint Venture Genalive Lands 950 Million RMB Genetic Testing Contract in Saudi Arabia.” Bioengineer.org, 2025. https://bioengineer.org/bgi-genomics-joint-venture-genalive-lands-%EF%BF%A5950-million-rmb-genetic-testing-contract-in-saudi-arabia/
  10. “BGI Genomics’ Joint Venture Genalive Lands RMB 950 Million Genetic Testing Contract.” SCBC Council, 2025. https://scbcouncil.com/en/bgi-genomics-joint-venture-genalive-lands-rmb-950-million-genetic-testing-contract-in-saudi-arabia/
  11. BGI Group. “BGI Group Executives Visit Saudi Arabia, Achieve Milestones in Healthcare, Innovation, and Talent Development.” Corporate Update, May 5, 2025. https://en.genomics.cn/en-news-7135.html
  12. BGI Group. MOU signing with Arabian Gulf University. https://www.bgi.com/global/news/video/BGI-signed-a-Memorandum-of-Understanding-MOU-with-Arabian-Gulf-University-AGU (geo-blocked; existence confirmed in BGI corporate channels and regional conference reporting)
  13. “Middle East experts blaze new trail to speak at the 17th International Conference on Genomics in Reproductive Health.” EurekAlert, August 11, 2022. https://www.eurekalert.org/news-releases/961568 (documents prior BGI / AGU Bahrain WGS collaboration)
  14. International Center for Genetic Disease, Brigham and Women’s Hospital / Harvard Medical School. “Bahrain National Genome Program.” https://icgd.bwh.harvard.edu/news/bahrain-national-genome-program
  15. “National genome project will benefit generations to come.” Gulf Daily News, 2026. https://www.gdnonline.com/Details/1339425
  16. Mbarek, Hamdi. “Qatar Genome team uses DRAGEN 4.2 for genomic analysis.” LinkedIn, 2024. https://www.linkedin.com/posts/hamdimbarek_dragen-v4-40k-activity-7154747419908268032-Piej
  17. “BeginNGS partners with Sidra Medicine for newborn screening.” LinkedIn, 2025. https://www.linkedin.com/posts/wajid-zahoor-bhat-28742a1a3_beginngs-newborn-screening-by-genome-sequencing-activity-7363913749994377217-iT3g
  18. BGI Group. “Omani Government Delegation Visits BGI Group.” Corporate Update, 2023. https://en.genomics.cn/en-news-6837.html
  19. “Kuwait DNA Sequencing Market Size and Outlook, 2025-2033.” Grand View Research. https://www.grandviewresearch.com/horizon/outlook/dna-sequencing-market/kuwait
  20. “Kuwait Third Generation Sequencing Market 2025-2031.” 6W Research. https://www.6wresearch.com/industry-report/kuwait-third-generation-sequencing-market
  21. “China’s BGI, Inspur added to US trade blacklist.” Al Jazeera / Reuters, March 3, 2023. https://www.aljazeera.com/economy/2023/3/3/chinas-bgi-inspur-added-to-us-trade-blacklist
  22. “BGI Group Companies added to Export Ban Entity List.” Digital Policy Alert, March 2023. https://digitalpolicyalert.org/event/9962-bgi-group-companies-added-to-export-ban-entity-list
  23. “BIS Imposes Export Restrictions on BGI Group.” Ropes and Gray, April 2023. https://www.ropesgray.com/en/insights/alerts/2023/04/bis-imposes-export-restrictions-on-bgi-group-the-worlds-largest-genomics-company
  24. “BIOSECURE Act Enacted.” Ropes and Gray, January 2026. https://www.ropesgray.com/en/insights/alerts/2026/01/biosecure-act-enacted
  25. “The BIOSECURE Act and Its Potential Implications.” Goodwin Law, 2024. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-the-biosecure-act-and-its-potential-implications
  26. “China’s gene-sequencing giant BGI to join UAE genome project.” Xinhua / EyeShenzhen, December 13, 2019. https://www.eyeshenzhen.com/content/2019-12/13/content_22700201.htm
  27. “China’s BGI Group to Join UAE’s Genome Programme.” Yicai Global, December 2019. https://www.yicaiglobal.com/news/china-bgi-group-to-join-uae-genome-programme
  28. “Chinese Genome Sequencing Firm to Supply Tech to Abu Dhabi Personalized Health Care Project.” Caixin Global, December 13, 2019. https://www.caixinglobal.com/2019-12-13/chinese-genome-sequencing-firm-to-supply-tech-to-abu-dhabi-personalized-health-care-project-101493721.html
  29. Department of Health Abu Dhabi. “DoH and M42 Collaborate to Enhance Precision Medicine Capabilities.” https://www.doh.gov.ae/en/news/doh-and-m42-collaborate-to-enhance-precision-medicine-capabilities-in-the-emirate
  30. M42. “Emirati Genome Program.” https://m42.ae/what-we-do/integrated-health-solutions/emirati-genome-program/
  31. SMEX. “Comparison PDPL (KSA) / GDPR.” 2022. https://smex.org/wp-content/uploads/2022/02/En-Comparaison-PDPL-KSA_GDPR.pdf
  32. Securiti.ai. “Understanding Saudi Arabia’s Personal Data Protection Law.” https://securiti.ai/saudi-arabia-personal-data-protection-law/
  33. Bird and Bird. “Health data under the Personal Data Protection Law.” 2025. https://www.twobirds.com/en/insights/2025/saudi-arabia-health-data-under-the-personal-data-protection-law

Similar Posts